Compound ID | 975
EXEG1706
| Spectrum of activity: | Gram-negative |
| Details of activity: | Designed for treatment of infections caused by drug resistant bacterial strains. It was found to be active against MRSA including quinolone resistant strains that ranged form 2-16μg/ml and toxicity levels in macrophages of LC50 of 400μg/ml |
| Description: | AV-Gay Y, Pick N, Goode RL, et al. EXEG1706: a novel antimicrobial agent against methicillin-resistant Staphylococcus aureus.43rd-ICAAC 2003;269 |
| Institute where first reported: | eXegenics (Opko Health, USA) |
| Year first mentioned: | 2003 |
| Highest developmental phase: | Preclinical |
| Development status: | Inactive |
| Reason Dropped: | possible toxicity? Company finance? |
| External links: | |
| Citation: |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.